Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

960.96 +2.32 (+0.24%)
Streaming Delayed Price Updated: 10:41 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Why the quality investor may take a look at NASDAQ:REGN.
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
The 7 Best Value Stocks to Buy in August
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy. 
Via InvestorPlace
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related  
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics
Via Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
Regeneron Surmounts Its 200-Day Line On A Handy Second-Quarter Beat
Shares have been trapped below their 200-day moving average since late June. 
Via Investor's Business Daily
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Regeneron Pharmaceuticals Earnings Preview
Via Benzinga
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash... 
Via Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
2 Top Stocks to Buy in August and Hold Forever
These companies won't disappoint long-term investors. 
Via The Motley Fool
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90... 
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $58,000 Today
Via Benzinga
Market Rally Under Pressure As Yields Soar; Amazon, ELF, Caterpillar Are Earnings Winners: Weekly Review
Amazon, ELF and CAT were earnings winners, but there were big losers too. 
Via Investor's Business Daily
Why Is Regeneron Pharmaceuticals Moving Higher Today?
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Stre 
Via Benzinga
US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month
Stocks appear to be entrenched in an August swoon and it remains to be seen if big tech earnings provide a boost. 
Via Benzinga
P/E Ratio Insights for Regeneron Pharmaceuticals
Via Benzinga
Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points
Investors looking to give their portfolio a boost should consider one of these leading biotech names, which are undervalued right now. 
Via InvestorPlace
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens,... 
Via Benzinga
If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names
These are the best biotech stocks that investors can invest in. That's because they are sector leaders that can make you a millionaire. 
Via InvestorPlace
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These three undervalued biotech stocks could have plenty of room to run if their efforts to push out promising pipeline drugs are successful. 
Via InvestorPlace
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Why Are Kodiak Sciences Shares Trading Lower Today?
Kodiak Sciences Inc (NASDAQ: KOD) shares are tumbling after the company released topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate, for... 
Via Benzinga
Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and  
Via Benzinga
3 Pharma Stocks That AI is Loving in July
Artificial intelligence recommends that these are the three stocks to consider when investing in pharma stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.